Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson’s disease

Rasagiline is a monoamine oxidase B inhibitor with demonstrated efficacy and safety in patients with Parkinson’s disease (PD). We recently conducted the first randomized, double-blind, placebo-controlled trial of rasagiline in Japanese patients with early PD and now report the results of its open-la...

Descripción completa

Detalles Bibliográficos
Autores principales: Hattori, Nobutaka, Takeda, Atsushi, Takeda, Shinichi, Nishimura, Akira, Kitagawa, Tadayuki, Mochizuki, Hideki, Nagai, Masahiro, Takahashi, Ryosuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2019
Materias:
Neurology and Preclinical Neurological Studies - Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449288/
https://www.ncbi.nlm.nih.gov/pubmed/30689042
http://dx.doi.org/10.1007/s00702-018-1964-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449288/
https://www.ncbi.nlm.nih.gov/pubmed/30689042
http://dx.doi.org/10.1007/s00702-018-1964-3

Ejemplares similares